Mazdutide vs Semaglutide: GLP-1 Agonists Compared

Introduction#

The landscape of incretin-based therapies for obesity and type 2 diabetes is expanding rapidly beyond single-target GLP-1 receptor agonists. Mazdutide (IBI362/LY3305677) represents the dual GLP-1/glucagon receptor agonist approach, while semaglutide (Ozempic/Wegovy) remains the benchmark single-target GLP-1 RA against which all newer agents are measured.

This comparison examines how mazdutide's dual agonist mechanism compares to semaglutide's established single-target approach across efficacy, safety, evidence quality, and clinical availability. Both are once-weekly subcutaneous peptides with C18-C20 fatty acid modifications for albumin binding and extended half-life, but they diverge fundamentally in their receptor pharmacology and the breadth of their clinical evidence.

Quick Comparison Table#

Mechanism of Action Comparison#

Mazdutide#

Mazdutide is a synthetic oxyntomodulin analog that simultaneously activates both the GLP-1 receptor and the glucagon receptor. The GLP-1 component provides the established incretin effects: enhanced glucose-dependent insulin secretion, suppressed glucagon release (paradoxically, the GLP-1-mediated pancreatic glucagon suppression coexists with hepatic glucagon receptor activation), delayed gastric emptying, and central appetite suppression through hypothalamic signaling.

The glucagon receptor agonism adds metabolic effects not achievable with GLP-1 alone: increased hepatic glucose output (counterbalanced by GLP-1-mediated insulin secretion), enhanced fatty acid oxidation, increased energy expenditure, and potential reduction in hepatic lipid content. This dual mechanism aims to achieve greater weight loss through complementary pathways -- GLP-1 reducing caloric intake while glucagon increases energy expenditure.

Semaglutide#

Semaglutide is a selective GLP-1 receptor agonist that mimics the endogenous incretin hormone GLP-1. It binds exclusively to the GLP-1R, a class B GPCR expressed on pancreatic beta cells, hypothalamic neurons, and gastrointestinal tract cells.

The mechanism produces glucose-dependent insulin secretion, suppressed inappropriate glucagon release, delayed gastric emptying, and powerful central appetite reduction through hypothalamic and brainstem satiety circuits. Semaglutide's C18 fatty diacid chain at Lys26 enables strong albumin binding, resulting in a half-life of approximately 7 days and supporting once-weekly dosing.

Evidence and Research Comparison#

Mazdutide Clinical Evidence#

Mazdutide's evidence base, while growing, is primarily from Chinese clinical trials:

• Phase III obesity trial: At the 9 mg dose, participants achieved up to 20.1% body weight reduction at 60 weeks, with dose-dependent effects across the 3 mg, 6 mg, and 9 mg arms
• Phase III diabetes trial: Significant HbA1c reductions of up to -2.15% versus placebo in patients with type 2 diabetes, alongside meaningful weight loss
• China approval: Approved in June 2025 for chronic weight management in Chinese adults with obesity
• Global trials: International Phase III programs are ongoing but results have not yet been reported

Semaglutide Clinical Evidence#

Semaglutide has one of the most comprehensive clinical evidence programs in metabolic medicine:

• STEP program: Multiple Phase III trials across diverse populations. STEP 1 (n=1,961) demonstrated 14.9% mean weight loss at 68 weeks. STEP 5 showed 16.0% at 104 weeks, demonstrating sustained efficacy
• SUSTAIN program: Established glycemic control superiority over comparators in type 2 diabetes across multiple trials
• SELECT trial: Landmark cardiovascular outcome trial (n=17,604) showing 20% reduction in major adverse cardiovascular events in overweight/obese adults without diabetes
• Real-world data: Years of post-marketing surveillance across millions of prescriptions globally
• Oral formulation: Rybelsus demonstrated oral bioavailability, expanding administration options

Evidence Quality Assessment#

The gap in evidence quality is substantial. Semaglutide benefits from over a decade of clinical development, large multi-ethnic trial populations, cardiovascular outcome data, and extensive post-marketing surveillance. Mazdutide's data, while promising, is limited to Chinese populations and lacks cardiovascular outcome data, long-term safety follow-up, and head-to-head comparisons with established GLP-1 RAs.

Side Effects and Safety Comparison#

Mazdutide Side Effects#

Clinical trial data shows a side effect profile consistent with incretin-based therapies, though the glucagon component introduces considerations:

• Gastrointestinal: Nausea, diarrhea, and vomiting are the most common adverse events, similar to other GLP-1 RAs
• Hepatic considerations: Glucagon receptor activation affects hepatic metabolism; long-term hepatic safety monitoring is ongoing
• Dose-dependent tolerability: Higher doses (9 mg) show greater GI side effects but also greater efficacy
• Limited long-term data: Post-marketing surveillance is limited to the Chinese market since 2025

Semaglutide Side Effects#

Semaglutide's safety profile is the most extensively characterized among GLP-1 RAs:

• Gastrointestinal: Nausea (approximately 44% in STEP 1), diarrhea, vomiting, and constipation; typically transient during dose escalation
• Cardiovascular: Proven safety and benefit (SELECT trial); transient heart rate increases of 1-4 bpm
• Pancreatitis: Rare cases reported; monitoring recommended
• Gallbladder events: Increased cholelithiasis risk observed across GLP-1 RA class
• Thyroid: Boxed warning for medullary thyroid carcinoma based on rodent data; not observed in human studies

Dosing and Administration Comparison#

Mazdutide Dosing#

• Once-weekly subcutaneous injection
• Dose escalation from 3 mg to 6 mg to 9 mg
• Administered in the abdomen, thigh, or upper arm
• No oral formulation available

Semaglutide Dosing#

• Injectable (Ozempic/Wegovy): Once-weekly SC; dose escalation from 0.25 mg to target dose of 1.0 mg (diabetes) or 2.4 mg (obesity)
• Oral (Rybelsus): Daily oral tablet; 3 mg, 7 mg, or 14 mg doses taken on an empty stomach with minimal water
• Auto-injector pens available for self-administration

Use Case Recommendations#

When Semaglutide Is Preferred#

• First-line obesity treatment: Extensive evidence supports efficacy and safety
• Cardiovascular risk reduction: Only GLP-1 RA with proven MACE reduction in non-diabetic obese patients
• Patients requiring oral option: Rybelsus provides non-injectable alternative
• Clinical settings requiring proven safety data: Post-marketing experience across millions of patients

When Mazdutide May Be Considered#

• Research into dual agonist mechanisms: The GLP-1/glucagon approach represents a distinct pharmacological strategy
• Patients in approved markets: Currently limited to China
• Potential for greater weight loss: If head-to-head data confirms the efficacy signal from Phase III trials

Can They Be Combined?#

Combining mazdutide with semaglutide would not be appropriate as both activate the GLP-1 receptor, creating overlapping pharmacology with additive GI side effects and no clear benefit over either agent alone. The comparison is best understood as an either/or choice between single and dual agonist approaches.

For researchers interested in the dual agonist landscape, survodutide (GLP-1/glucagon) and tirzepatide (GLP-1/GIP) represent alternative dual-target strategies worth examining.

Verdict#

Semaglutide remains the gold standard among incretin-based therapies, backed by an unmatched clinical evidence program that includes cardiovascular outcome data, long-term safety surveillance, multiple formulations, and global regulatory approvals. It is the appropriate first choice for most clinical and research applications in metabolic disease.

Mazdutide represents a promising next-generation approach, and its Phase III weight loss data (up to 20.1%) suggests that dual GLP-1/glucagon agonism may achieve meaningfully greater weight reduction than GLP-1 alone. However, the absence of cardiovascular outcome data, limited ethnic diversity in clinical trials, and restricted availability currently limit its positioning.

The field would benefit from head-to-head trials comparing these agents directly, as the cross-trial comparison of 20.1% versus 14.9-16.0% weight loss, while suggestive, cannot account for differences in trial design, patient populations, and dose optimization.

Explore full profiles of Mazdutide and Semaglutide, or see how they compare to Tirzepatide and Survodutide. Use our GLP-1 Saturation Calculator for steady-state pharmacokinetic modeling.

Further Reading#

• Mazdutide Overview and Research Guide
• Mazdutide Side Effects
• Mazdutide Dosing Protocols
• Semaglutide Overview and Research Guide
• Semaglutide Side Effects
• Semaglutide Dosing Protocols